18
Aug
The rising trade disputes between Washington and Brussels reached a pivotal point when former U.S. President Donald Trump decided to abandon proposals to introduce an unusually steep tariff—allegedly 250 percent—on pharmaceutical goods imported from the European Union. This move, included in a broader trade agreement, represents a crucial development in the prolonged discussions between the two significant economic forces and provides a temporary relief for businesses on both sides of the Atlantic.The conflict originated during a time of escalating trade tensions when Washington aimed to address perceived ongoing disparities and unjust practices across industries like agriculture, technology, and healthcare. Pharmaceuticals…